US-based NanoSmart Pharmaceuticals and biotechnology firm NanoValent Pharmaceuticals have entered into strategic research collaboration for developing enhanced cancer pharmaceuticals.
Pursuant to the terms of the research collaboration agreement, NanoSmart Pharmaceuticals and NanoValent Pharmaceuticals will explore the feasibility of jointly developing an anti-nuclear antibody (ANA)-conjugated liposomal doxorubicin nanoparticle to treat ovarian cancer and other solid tumors.
In the joint project, NanoValent’s hybrid polymerized liposomal nanoparticle will be combined with NanoSmart’s patented anti-nuclear antibody platform technology.
NanoValent’s hybrid polymerized liposomal nanoparticle can be loaded with chemotherapeutic substances for safer drug delivery. NanoSmart’s anti-nuclear antibody platform technology targets areas of necrosis present in all solid tumors.
NanoValent president and CEO Dr Doug Dolginow noted that the company’s HPLN nanocontainer lowers the toxic side effects of drugs like doxorubin, widening the safety window of the drug.
"The combination of our respective platforms provides a substantial opportunity to improve treatment options for a wide variety of cancers," Dr Dolginow added.